The degree of neuromuscular blockade that occurs in an individual patient following the administration of competitive neuromuscular blocking agents cannot be accurately predicted because of the large individual variation in the pharmacokinetics and pharmacodynamics of these agents. Without monitoring of the neuromuscular blockade, this unpredictability predisposes to the occurrence of residual curarisation with its potentially lethal consequences. Variable rate continuous infusion of a short-acting competitive neuromuscular blocking agent with monitoring of the neuromuscular blockade is a flexible and accurate method for maintaining a precise degree of neuromuscular blockade during prolonged surgical procedures which ensures reliable reversability of the residual neuromuscular blockade. A system for the continuous infusion of atracurium with manual monitoring of the neuromuscular blockade is described, together with the results of a study demonstrating its efficacy.
BeecherHI, ToddDP. A study of deaths associated with anesthesia and surgery based on a study of 599,548 anesthetics in 10 institutions, 1948–1953 inclusive. Ann Surg1954; 50:2–34.
6.
LunnJN, HunterAR, ScottDB. Anaesthesia related surgical mortality. Anaesthesia1983; 38:1090–1096.
7.
Vourc'hG, HattonF, TiretL, DesmontsJM. Etude epidemiologique sur les complications de l'anesthesia en France. Bull Acad Nat Med (Paris)1983; 167:939–945.
8.
MillerRD, SavareseJJ. Pharmacology of muscle relaxants, their antagonists, and monitoring neuromuscular function. Anesthesia. MillerRD, ed. Churchill Livingstone, New York 1981; 1:518.
KatzR.Clinical neuromuscular pharmacology of pancuronium. Anesthesiology1971; 34:550–556.
11.
KatzRL. Neuromuscular effects of d-tubucurarine, edrophonium and neostigmine in man. Anesthesiology1967; 28:327–336.
12.
HennisPJ, StanskiDR. Pharmacokinetic and pharmacodynamic factors that govern the clinical use of muscle relaxants. Seminars in Anesthesia1985; IV:21–30.
MillerRD. Pharmacokinetics of competitive muscle relaxants. Br J Anaesth1982; 54:161–167.
15.
BuzelloW, AgostonS.Comparative clinical pharmacokinetics of tubocurarine, gallamine, alcuronium and pancuronium. Anaesthetist1978; 27:313–318.
16.
HullCJ, EnglishMJM, SibbaldA.Fazadinum and pancuronium: A pharmacodynamic study. Br J Anaesth1980; 52:1209–1220.
17.
ShanksCA, SomogyiAA, TriggsEJ. Dose-response and plasma concentration-response relationships of pancuronium in man. Anesthesiology1979; 51:111–118.
18.
EvansMA, ShanksCA, BrownKF, TriggsEJ. Pharmacokinetic and pharmacodynamic modelling of pancuronium. Eur J Clin Pharmacol1984; 26:243–251.
19.
MillerRD, WayWL, DolanWM, StevensWC, EgerEIII.Comparative neuromuscular effects of pancuronium, gallamine, and succinylcholine during Forane and halothane anesthesia in man. Anesthesiology1971; 35:509–514.
20.
FogdallRP, MillerRD. Neuromuscular effects of enflurance alone and in combination with d-tubucurarine, pancuronium and succinylcholine in man. Anesthesiology1975; 42:173–178.
21.
MillerRD, WayWL, DolanWM, StevensWC, EgerEIII.The dependence of pancuronium and d-tubocurarine induced neuromuscular blockades on alveolar concentrations of halothane and Forance. Anesthesiology1972; 37:573–581.
22.
StanskiDR, HamJ, MillerRD, SheinerLB. Time dependent increase in sensitivity to dTC during enflurane anesthesia. Anesthesiology1979; 51:S269.
23.
SkanksCA, SomogyiAA, RamzanMI, TriggsEJ. Tubocurarine and pancuronium: a pharmacokinetic view. Anaesth Intens Care1980; 8:4–12.
24.
DuvaldestinP, SaadaJ, BergerJL, D'HollanderA, DesmontsJM. Pharmacokinetics, pharmacodynamics and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology1982; 56:36–40.
25.
CronnellyR, FisherDM, MillerRD, GencarelliP, Nguyen-GruenkeL, CastagnoliNJr. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. Anesthesiology1983; 58:405–408.
NormanJ.Pharmacokinetics of non-depolarizing muscle relaxants. Clinics in Anesthesiology1985; 3:273–281.
28.
AliHH, SavareseJJ. Monitoring of neuromuscular function. Anesthesiology1976; 45:218–251.
29.
Viby-MogensenJ.Clinical assessment of neuromuscular transmission. Br J Anaesth1982; 54:209–223.
30.
EagerBM, FlynnPJ, HughesR.Infusion for atracurium for long surgical procedures. Br J Anaesth1984; 56:447–452.
31.
NoldgeG, HinksenH, BuzelloW.Comparison between the continuous infusion of vecuronium and the intermittent administration of pancuronium and vercuronium. Br J Anaesth1984; 56:473–477.
32.
D'HollanderAA, CzeruckiR, DevilleA, CuvelierF.Stable muscle relaxation during abdominal surgery using combined intravenous bolus and demand infusion: clinical appraisal with Org NC45. Canad Anaesth Soc J1982; 29:136–141.
33.
AndersenBN, AndersenJV, SchurizekBA, JuhlB.Residual curarization, a comparative study of atracurium and pancuronium. Acta Anaesth Scand1985; supplement 80:68.
34.
HughesR.Atracurium — The first years. Clinics in Anaesthesiology1985; 3:331–345.
35.
NewtonDEF. Vecuronium — continuous infusion in general clinical practice. Clinical experience with norcuron (ORGNC45, vecuronium bromide). AgostonS, BowmanWC, MillerRD, Viby-MogensenJ, eds. Current Clinical Practice Series II. Excerpta Medica, Amsterdam1983; 109–114.
36.
AliHH, SavareseJJ, BastaSJ, MossJ, GionfriddoM.Evaluation of cumulative properties of three new non-depolarizing neuromuscular blocking drugs BWA44U, atracurium and vecuronium. Br J Anaesth1983; 55:107S–112S.
37.
HughesR, ChappleDJ, The pharmacology of atracurium, a new competitive neuromuscular blocking agent. Br J Anaesth1981; 53:31–44.
38.
RitchieG, EbertJP, JannetTC, KissinI, SheppardLC. Automatic control of muscle relaxation in surgical patients. Anesthesiology1983; 59:A168.
39.
BrownBH, AsburyJ, LinkensDA, PerksR, AnthonyM.Closed-loop control of muscle relaxation during surgery. Clin Phys Physiol Meas1980; 1:203–210.
40.
KopmanAF, LawsonD.Millamperage requirements for supramaximal stimulation of the ulnar nerve with surface electrodes. Anesthesiology1984; 61:83–85.
